Is it possible? One antibody for all COVID variants?
"Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection"
"...we employed an unbiased screening approach and successfully isolated two antibodies from individuals with only exposure to ancestral SARS-CoV-2. One of these antibodies, CYFN1006-1, exhibited robust cross-neutralization against a spectrum of SARS-CoV-2 variants, including the latest KP.2, KP.3 and XEC, with consistent IC50 values ranging from ~1 to 5?ng/mL. It also displayed broad neutralization activity against SARS-CoV and related sarbecoviruses. Structural analysis revealed that these antibodies target shared hotspot but mutation-resistant epitopes, with their Fabs locking receptor binding domains (RBDs) in the “down” conformation through interactions with adjacent Fabs and RBDs, and cross-linking Spike trimers into di-trimers. In vivo studies conducted in a JN.1-infected hamster model validated the protective efficacy of CYFN1006-1."
If a human could, indeed, generate such a broadly reactive antibody, then AI should be able to do this as well.
Assistant Professor at Georgetown University School of Medicine
11 小时前Neutralizing antibodies with robust autologous neutralization activity exhibit reduced effectiveness against future variants, especially those obtained early in the pandemic from individuals infected or vaccinated with the ancestral strain. To date, the majority of antibodies exhibiting cross-neutralization activities were isolated from donors with prior SARS infection, multiple vaccinations or infections, or possess hybrid immunity resulting from vaccinations and infections20,27. Herein, we identified antibodies capable of potently neutralizing all major SARS-CoV-2 variants, from a human donor with ancestral virus exposure exclusively. Notably, considering the timing of sample collection and the donor’s age, it is highly unlikely that this individual had prior exposure to either the SARS-CoV-2 vaccine or SARS-CoV infection. From this donor, we cloned two antibodies, both bearing the rare IGHV5-51 heavy-chain gene but paired with different light-chain genes. Interestingly, while these antibodies demonstrated similarly high potency in neutralizing SARS-CoV-2 variants, they exhibited varying degrees of efficacy in neutralizing SARS-CoV and related animal sarbecoviruses.